NAPLEX Practice Question # 11

Naplex Examination:

Take Practice # 11 for your upcoming Exam:


Naplex Practice Questions


Angiotensin II type I receptor antagonists ( Pharmacy Review)


Th is class of drugs has been one of the fastest growing groups of drugs for the treatment of hypertension. Currently, eight agents are available: azilsartan (Edarbi®), candesartan cilexetil (Atacand®), eprosartan (Teveten®), irbesartan (Avapro®), losartan (Cozaar®), olmesartan (Benicar®), telmisartan (Micardis®), and valsartan (Diovan®).


Th is class of drugs works by blocking the binding of angiotensin II to the angiotensin II receptors. By blocking the receptor site, these agents inhibit the vasoconstrictor eff ects of angiotensin II while also preventing the release of aldosterone from the adrenal glands. Th ese two properties of angiotensin II have been shown to be important causes for developing hypertension. Clinically, angiotensin receptor blockers appear to be equally eff ective for the treatment of hypertension as ACE inhibitors.

Precautions and monitoring eff ects

(1) Similar to ACE inhibitors, increases in serum potassium levels can occur, especially in patients receiving potassium-sparing diuretics. When used alone, hyperkalemia has not been reported to be severe enough to require stopping its use. However, as in patients receiving ACE inhibitors, potassium levels need to be monitored closely in those with compromised renal function.

Leave a Reply